1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceuticals in the United Kingdom

Pharmaceuticals in the United Kingdom

  • September 2016
  • -
  • MarketLine
  • -
  • 36 pages

Summary
Pharmaceuticals in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the United Kingdom

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the United Kingdom

Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom pharmaceuticals market with five year forecasts

Synopsis
Essential resource for top-line data and analysis covering the United Kingdom pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
What was the size of the United Kingdom pharmaceuticals market by value in 2015?

What will be the size of the United Kingdom pharmaceuticals market in 2020?

What factors are affecting the strength of competition in the United Kingdom pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitors in the United Kingdom's pharmaceuticals market?

Key Highlights
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.

The UK pharmaceuticals market had total revenues of $29.3bn in 2015, representing a compound annual growth rate (CAGR) of 8.8% between 2011 and 2015.

The United Kingdom contains two of the top ten Pharmaceutical companies globally in Astra Zeneca and GSK and as such has a busy manufacturing and RandD sector.

The performance of the market is forecast to decelerate, with an anticipated CAGR of 7.6% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $42.2bn by the end of 2020.

Table Of Contents

Pharmaceuticals in the United Kingdom
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
GlaxoSmithKline Plc
Novartis AG
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: United Kingdom pharmaceuticals market value: $ billion, 2011-15
Table 2: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2015
Table 3: United Kingdom pharmaceuticals market share: % share, by value, 2015
Table 4: United Kingdom pharmaceuticals market value forecast: $ billion, 2015-20
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: key financials ($)
Table 10: GlaxoSmithKline Plc: key financials (£)
Table 11: GlaxoSmithKline Plc: key financial ratios
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials ($)
Table 14: Novartis AG: key financial ratios
Table 15: United Kingdom size of population (million), 2011-15
Table 16: United Kingdom gdp (constant 2005 prices, $ billion), 2011-15
Table 17: United Kingdom gdp (current prices, $ billion), 2011-15
Table 18: United Kingdom inflation, 2011-15
Table 19: United Kingdom consumer price index (absolute), 2011-15
Table 20: United Kingdom exchange rate, 2011-15

List of Figures
Figure 1: United Kingdom pharmaceuticals market value: $ billion, 2011-15
Figure 2: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 3: United Kingdom pharmaceuticals market share: % share, by value, 2015
Figure 4: United Kingdom pharmaceuticals market value forecast: $ billion, 2015-20
Figure 5: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2015
Figure 6: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2015
Figure 7: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2015
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2015
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2015
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2015
Figure 11: AstraZeneca PLC: revenues and profitability
Figure 12: AstraZeneca PLC: assets and liabilities
Figure 13: GlaxoSmithKline Plc: revenues and profitability
Figure 14: GlaxoSmithKline Plc: assets and liabilities
Figure 15: Novartis AG: revenues and profitability
Figure 16: Novartis AG: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.